RS58580B1 - Imunomodulatori - Google Patents
ImunomodulatoriInfo
- Publication number
- RS58580B1 RS58580B1 RS20190419A RSP20190419A RS58580B1 RS 58580 B1 RS58580 B1 RS 58580B1 RS 20190419 A RS20190419 A RS 20190419A RS P20190419 A RSP20190419 A RS P20190419A RS 58580 B1 RS58580 B1 RS 58580B1
- Authority
- RS
- Serbia
- Prior art keywords
- dmf
- resin
- fmoc
- solution
- frit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094281P | 2014-12-19 | 2014-12-19 | |
| PCT/US2015/066272 WO2016100608A1 (en) | 2014-12-19 | 2015-12-17 | Immunomodulators |
| EP15820775.3A EP3233887B1 (en) | 2014-12-19 | 2015-12-17 | Immunomodulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS58580B1 true RS58580B1 (sr) | 2019-05-31 |
Family
ID=55071225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20190419A RS58580B1 (sr) | 2014-12-19 | 2015-12-17 | Imunomodulatori |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9944678B2 (OSRAM) |
| EP (1) | EP3233887B1 (OSRAM) |
| JP (1) | JP6705823B2 (OSRAM) |
| KR (1) | KR102590776B1 (OSRAM) |
| CN (1) | CN107223129B (OSRAM) |
| AR (1) | AR103182A1 (OSRAM) |
| AU (1) | AU2015364573A1 (OSRAM) |
| BR (1) | BR112017012704A2 (OSRAM) |
| CA (1) | CA2971266A1 (OSRAM) |
| CY (1) | CY1121571T1 (OSRAM) |
| DK (1) | DK3233887T3 (OSRAM) |
| EA (1) | EA033721B1 (OSRAM) |
| ES (1) | ES2719135T3 (OSRAM) |
| HR (1) | HRP20190575T1 (OSRAM) |
| HU (1) | HUE044027T2 (OSRAM) |
| IL (1) | IL252896A0 (OSRAM) |
| LT (1) | LT3233887T (OSRAM) |
| MX (1) | MX2017008160A (OSRAM) |
| PL (1) | PL3233887T3 (OSRAM) |
| PT (1) | PT3233887T (OSRAM) |
| RS (1) | RS58580B1 (OSRAM) |
| SG (1) | SG11201704821VA (OSRAM) |
| SI (1) | SI3233887T1 (OSRAM) |
| SM (1) | SMT201900253T1 (OSRAM) |
| TR (1) | TR201906470T4 (OSRAM) |
| TW (1) | TW201629087A (OSRAM) |
| WO (1) | WO2016100608A1 (OSRAM) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2666730C2 (ru) | 2012-12-07 | 2018-09-12 | Кемосентрикс, Инк. | Диазольные лактамы |
| MX380553B (es) | 2014-09-11 | 2025-03-12 | Bristol Myers Squibb Co | Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1. |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| PT3297438T (pt) | 2015-05-21 | 2022-01-25 | Chemocentryx Inc | Moduladores de ccr2 |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) * | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| BR112018070361A2 (pt) | 2016-04-07 | 2019-01-29 | Chemocentryx Inc | redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| EA038019B1 (ru) | 2016-05-19 | 2021-06-23 | Бристол-Маерс Сквибб Компани | Иммуномодуляторы для пэт-визуализации |
| IL308894A (en) | 2016-10-14 | 2024-01-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| WO2018085750A2 (en) * | 2016-11-07 | 2018-05-11 | Bristol-Myers Squibb Company | Immunomodulators |
| KR20240023665A (ko) | 2016-12-23 | 2024-02-22 | 더 존스 홉킨스 유니버시티 | Pd-l1 발현에 기반한 종양 및 면역 세포 영상화 |
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| US11066445B2 (en) * | 2017-06-23 | 2021-07-20 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of PD-1 |
| IL273188B2 (en) | 2017-09-25 | 2023-03-01 | Chemocentryx Inc | Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor |
| JP7257393B2 (ja) * | 2017-10-03 | 2023-04-13 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤 |
| JP7386796B2 (ja) | 2017-11-14 | 2023-11-27 | グリーン クロス ラボ セル コーポレーション | 抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| MA50423A (fr) | 2018-01-08 | 2020-08-26 | Chemocentryx Inc | Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2 |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| US12331068B2 (en) | 2018-05-31 | 2025-06-17 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting CD73 |
| SG11202011651SA (en) | 2018-05-31 | 2020-12-30 | Ono Pharmaceutical Co | Biomarkers for determining the effectiveness of immune checkpoint inhibitors |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| TW202446772A (zh) | 2018-10-11 | 2024-12-01 | 日商小野藥品工業股份有限公司 | Ｓｔｉｎｇ促效化合物 |
| PL3873903T3 (pl) | 2018-10-31 | 2024-05-20 | Gilead Sciences, Inc. | Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1 |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| KR20210146348A (ko) | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| EP3946628A1 (en) | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020237081A1 (en) * | 2019-05-21 | 2020-11-26 | Bristol-Myers Squibb Company | Immunomodulators |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| JP7662156B2 (ja) | 2019-08-05 | 2025-04-15 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| AU2020350795A1 (en) | 2019-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Quantitative spatial profiling for LAG-3 antagonist therapy |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| KR20220092912A (ko) | 2019-11-07 | 2022-07-04 | 추가이 세이야쿠 가부시키가이샤 | 입체 장애가 큰 아미노산을 포함하는 펩티드 화합물의 제조 방법 |
| JP6880352B1 (ja) * | 2019-11-07 | 2021-06-02 | 中外製薬株式会社 | Ｋｒａｓ阻害作用を有する環状ペプチド化合物 |
| EP4054723A1 (en) | 2019-11-08 | 2022-09-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for melanoma |
| EP4567109A3 (en) | 2019-12-06 | 2025-09-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| JP2023510737A (ja) | 2020-01-06 | 2023-03-15 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤 |
| TW202421168A (zh) | 2020-03-20 | 2024-06-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
| KR20220161407A (ko) | 2020-03-30 | 2022-12-06 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | Method of cancer therapy |
| WO2021205631A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | Ｓｔｉｎｇ作動化合物 |
| CN113754736A (zh) * | 2020-06-02 | 2021-12-07 | 南京礼威生物医药有限公司 | 含酰肼结构的pd-l1环肽抑制剂 |
| EP4204095A1 (en) | 2020-08-28 | 2023-07-05 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| US20230381112A1 (en) | 2020-09-22 | 2023-11-30 | Vaccitech North America, Inc. | Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ |
| WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| EP4086272A1 (en) | 2021-05-07 | 2022-11-09 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing cyclic compounds comprising n-substituted amino acid residues |
| CA3219415A1 (en) * | 2021-05-07 | 2022-11-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical use of cyclic peptide compound |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| EP4351564A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| WO2023077090A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| CN118765285A (zh) | 2022-01-26 | 2024-10-11 | 百时美施贵宝公司 | 用于肝细胞癌的组合疗法 |
| US20230326022A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures |
| KR20250052397A (ko) | 2022-08-23 | 2025-04-18 | 오노 야꾸힝 고교 가부시키가이샤 | 이중 특이성 항체 |
| CN120731228A (zh) | 2022-12-21 | 2025-09-30 | 百时美施贵宝公司 | 肺癌的组合疗法 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025193572A1 (en) * | 2024-03-11 | 2025-09-18 | Bristol-Myers Squibb Company | Macrocyclic peptides useful as immunomodulators |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2141175B1 (en) | 2007-03-26 | 2016-07-27 | The University of Tokyo | Process for synthesizing cyclic peptide compound |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
| EP2647720B1 (en) | 2010-12-03 | 2019-06-19 | The University of Tokyo | Peptide library production method, peptide library, and screening method |
| CN103732238A (zh) | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
| CN104159911A (zh) * | 2012-03-07 | 2014-11-19 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的模拟肽化合物 |
| JP2015512910A (ja) | 2012-03-29 | 2015-04-30 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | ヒトｐｄ１のｂｃループに由来する免疫調節性環状化合物 |
| EP2858667A1 (en) * | 2012-06-06 | 2015-04-15 | Bionor Immuno AS | Hiv vaccine |
| WO2013182240A1 (en) | 2012-06-06 | 2013-12-12 | Polyphor Ag | Beta-hairpin peptidomimetics |
| JP2013253842A (ja) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法 |
| US9308236B2 (en) * | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| KR20150131269A (ko) | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| SG11201601685TA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | Cyclic peptidomimetic compounds as immunomodulators |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| MX380553B (es) | 2014-09-11 | 2025-03-12 | Bristol Myers Squibb Co | Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1. |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) * | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
-
2015
- 2015-12-16 US US14/971,352 patent/US9944678B2/en active Active
- 2015-12-17 EA EA201791216A patent/EA033721B1/ru not_active IP Right Cessation
- 2015-12-17 CA CA2971266A patent/CA2971266A1/en not_active Abandoned
- 2015-12-17 TR TR2019/06470T patent/TR201906470T4/tr unknown
- 2015-12-17 SI SI201530635T patent/SI3233887T1/sl unknown
- 2015-12-17 LT LTEP15820775.3T patent/LT3233887T/lt unknown
- 2015-12-17 EP EP15820775.3A patent/EP3233887B1/en active Active
- 2015-12-17 RS RS20190419A patent/RS58580B1/sr unknown
- 2015-12-17 PL PL15820775T patent/PL3233887T3/pl unknown
- 2015-12-17 DK DK15820775.3T patent/DK3233887T3/da active
- 2015-12-17 HU HUE15820775A patent/HUE044027T2/hu unknown
- 2015-12-17 JP JP2017532680A patent/JP6705823B2/ja active Active
- 2015-12-17 KR KR1020177019584A patent/KR102590776B1/ko active Active
- 2015-12-17 ES ES15820775T patent/ES2719135T3/es active Active
- 2015-12-17 MX MX2017008160A patent/MX2017008160A/es unknown
- 2015-12-17 SM SM20190253T patent/SMT201900253T1/it unknown
- 2015-12-17 HR HRP20190575TT patent/HRP20190575T1/hr unknown
- 2015-12-17 SG SG11201704821VA patent/SG11201704821VA/en unknown
- 2015-12-17 CN CN201580075897.7A patent/CN107223129B/zh active Active
- 2015-12-17 WO PCT/US2015/066272 patent/WO2016100608A1/en not_active Ceased
- 2015-12-17 AU AU2015364573A patent/AU2015364573A1/en not_active Abandoned
- 2015-12-17 PT PT15820775T patent/PT3233887T/pt unknown
- 2015-12-17 BR BR112017012704-0A patent/BR112017012704A2/pt not_active Application Discontinuation
- 2015-12-18 TW TW104142843A patent/TW201629087A/zh unknown
- 2015-12-18 AR ARP150104203A patent/AR103182A1/es unknown
-
2017
- 2017-06-14 IL IL252896A patent/IL252896A0/en unknown
-
2019
- 2019-04-25 CY CY20191100451T patent/CY1121571T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017012704A2 (pt) | 2018-03-06 |
| HRP20190575T1 (hr) | 2019-05-17 |
| PL3233887T3 (pl) | 2019-08-30 |
| WO2016100608A1 (en) | 2016-06-23 |
| SG11201704821VA (en) | 2017-07-28 |
| SI3233887T1 (sl) | 2019-04-30 |
| US20160176928A1 (en) | 2016-06-23 |
| HUE044027T2 (hu) | 2019-09-30 |
| KR102590776B1 (ko) | 2023-10-18 |
| LT3233887T (lt) | 2019-04-25 |
| JP2018504378A (ja) | 2018-02-15 |
| EP3233887B1 (en) | 2019-02-06 |
| CA2971266A1 (en) | 2016-06-23 |
| TR201906470T4 (tr) | 2019-05-21 |
| KR20170098872A (ko) | 2017-08-30 |
| IL252896A0 (en) | 2017-08-31 |
| EA033721B1 (ru) | 2019-11-20 |
| CN107223129B (zh) | 2022-01-04 |
| MX2017008160A (es) | 2017-09-18 |
| US9944678B2 (en) | 2018-04-17 |
| EP3233887A1 (en) | 2017-10-25 |
| SMT201900253T1 (it) | 2019-07-11 |
| AR103182A1 (es) | 2017-04-19 |
| EA201791216A1 (ru) | 2017-10-31 |
| AU2015364573A1 (en) | 2017-08-03 |
| PT3233887T (pt) | 2019-04-30 |
| TW201629087A (zh) | 2016-08-16 |
| CN107223129A (zh) | 2017-09-29 |
| CY1121571T1 (el) | 2020-05-29 |
| DK3233887T3 (da) | 2019-05-13 |
| JP6705823B2 (ja) | 2020-06-03 |
| ES2719135T3 (es) | 2019-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11492375B2 (en) | Cyclic peptide immunomodulators | |
| EP3271373B1 (en) | Immunomodulators | |
| EP3233887B1 (en) | Immunomodulators | |
| US11066445B2 (en) | Immunomodulators acting as antagonists of PD-1 | |
| EP3535280B1 (en) | Immunomodulators | |
| US9861680B2 (en) | Immunomodulators | |
| US10450347B2 (en) | Immunomodulators | |
| AU2017227777B2 (en) | Immunomodulators | |
| KR102538436B1 (ko) | 면역조정제 | |
| WO2016039749A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions |